EGFR and non-small cell lung carcinoma: Therefore, from the perspective of pharmacoeconomics, it is significant to evaluate the cost-effectiveness of osimertinib versus first-generation EGFR-TKI as the first-line treatment for previously untreated, EGFR mutation-positive advanced NSCLC.